Hyeok Lee
Sungkyunkwan University · 医学
研究室紹介
Professor Hyeok Lee's research lab specializes in gastrointestinal disorders, particularly focusing on the pathophysiology of irritable bowel syndrome (IBS) and functional gastrointestinal diseases. The lab investigates mucosal immune mechanisms, such as mast cell involvement in intestinal permeability, and explores novel therapeutic strategies, including pharmacological agents like venlafaxine for functional chronic pain and advanced drug delivery systems such as pH-responsive extracellular vesicles for cancer immunotherapy. The lab also examines drug-induced complications, including proton pump inhibitor (PPI)-associated hypomagnesmia, and evaluates treatment efficacy in viral hepatitis, particularly in East Asian populations. Overall, the lab bridges translational gastroenterology with innovative therapeutics and personalized medicine approaches.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15This study demonstrated a positive correlation between the number of mucosal mast cells and intestinal permeability, suggesting that mucosal mast cells play an important role for increased intestinal permeability in patients with IBS-D.
Venlafaxine, an SNRI antidepressant, significantly improved symptoms in young adult patients with FCP.
WCS group showed comparable migration rate and significantly more durable long-term stent patency compared with UCS group for the palliation of GOO in patients with inoperable gastric cancer.
Immunotherapy can potentially treat cancers on a patient-dependent manner. Most of the efforts expended on anticancer vaccination parallel the efforts expended on prototypical immunization in infectious diseases. In this study, we designed and synthesized pH-responsive extracellular vesicles (EVs) coupled with hyaluronic acid (HA), 3-(diethylamino)propylamine (DEAP), monophosphoryl lipid A (MPLA), and mucin 1 peptide (MUC1), referred to as HDEA@EVAT. HDEA@EVAT potentiated the differentiation and
There is increasing evidence and case reports regarding proton pump inhibitor (PPI)-induced hypomagnesemia. Our study aimed to clarify the relationship between PPI use and serum magnesium levels and to specify high-risk patients. We retrospectively studied 112 consecutive patients aged 20 years or older who were treated with PPI for ≥30 days and whose serum magnesium levels were available for the PPI treatment period. We compared the mean level of serum magnesium of the enrolled patients with PP
BACKGROUND/AIMS: Combination therapy with peginterferon and ribavirin is a standard therapy for western patients with chronic hepatitis C; however, its efficacy remains unclear in East Asian patients. We evaluated the efficacy and safety of administering peginterferon alfa-2a plus ribavirin in native Korean patients with chronic hepatitis C. METHODS: Seventy-five patients with detectable HCV RNA (52.0% male, median age: 50.8 years) were eligible for the study. The patients were treated with pegi